BLCO (Bausch & Lomb) Current Accrued Expense: $632 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BLCO Bausch & Lomb Corp BLCO
77 GF Score
Price $17.79
GF Value $18.40
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Bausch & Lomb Current Accrued Expense?

Bausch & Lomb BLCO +0.34% 77 Current Accrued Expense is $632 Mil as of Jun. 2026. GuruFocus rates BLCO with a GF Score™ of 77/100 and a GF Value™ of $18.40 (Fairly Valued). The stock has 5 warning signs investors should review.

Bausch & Lomb's Current Accrued Expense for the quarter that ended in Jun. 2026 was $632 Mil.

Bausch & Lomb's quarterly Current Accrued Expense declined from Dec. 2025 ($756 Mil) to Mar. 2026 ($603 Mil) but then increased from Mar. 2026 ($603 Mil) to Jun. 2026 ($632 Mil).

Bausch & Lomb's annual Current Accrued Expense increased from Dec. 2023 ($394 Mil) to Dec. 2024 ($652 Mil) and increased from Dec. 2024 ($652 Mil) to Dec. 2025 ($756 Mil).

Bausch & Lomb Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Bausch & Lomb's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bausch & Lomb Current Accrued Expense Chart

Bausch & Lomb Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial 224.00 363.00 394.00 652.00 756.00

Bausch & Lomb Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 730.00 775.00 756.00 603.00 632.00
BLCO
77GF Score
Bausch & Lomb Corp BLCO
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bausch & Lomb Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $632 Mil mean?
Bausch & Lomb (BLCO) has a Current Accrued Expense of $632 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Bausch & Lomb and its competitors.
Is Bausch & Lomb's Current Accrued Expense too high?
Bausch & Lomb's current Current Accrued Expense is $632 Mil. Overall, Bausch & Lomb has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bausch & Lomb's Current Accrued Expense compare to ISRG and BDX?
Bausch & Lomb's Current Accrued Expense of $632 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Medical Devices & Instruments company?
A good Current Accrued Expense depends on the Medical Devices & Instruments industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Bausch & Lomb and its competitors. Bausch & Lomb's current Current Accrued Expense is $632 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bausch & Lomb stock overvalued right now?
Based on GuruFocus' analysis, Bausch & Lomb (BLCO) is currently considered Fairly Valued. The stock's GF Value™ is $18.40, compared to a current price of $17.79 — trading 3.3% below its estimated fair value. The current Current Accrued Expense is $632 Mil. Bausch & Lomb's overall GF Score™ is 77/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Bausch & Lomb (BLCO), the current Current Accrued Expense is $632 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bausch & Lomb (BLCO) Overvalued in 2026?

Based on GuruFocus' analysis, Bausch & Lomb stock appears to be undervalued. The current stock price of $17.79 is trading 3.3% below its estimated GF Value™ of $18.40. GuruFocus considers Bausch & Lomb to be Fairly Valued.

Key valuation signals for BLCO:

  • Current Accrued Expense: $632 Mil
  • GF Value™: $18.40 vs. price of $17.79 (3.3% below fair value)
  • GF Score™: 77/100 with 5 warning signs

No single metric tells the full story. See the BLCO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bausch & Lomb Business Description

Other Exchanges S2L:GermanyBLCO:Canada
Address 520 Applewood Crescent, Vaughan, ON, CAN, L4K 4B4
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
77GF Score

Get the complete analysis for BLCO

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.79
Price
$18.40
GF Value